FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FSE: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced the appointments of Dr. Lakshmi P. Kotra and Joseph L. Romano to its board of directors, effective Nov. 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the board of directors. Dr. Kotra, an academic entrepreneur, has contributed to a number of important drug discovery and development projects, including metabolic disorders, neurodegenerative and immunological disorders, anti-HIV drugs, antibacterials, and antimalarials. He is the recipient of several awards and has authored/co-authored over 130 publications and delivered over 140 scientific talks internationally. Romano is the founding member of Romano Law Firm and has dedicated his law career to helping victims of serious personal injury and motor vehicle accidents. A graduate of Osgoode Hall Law School, Romano has appeared at all levels of court in Ontario, Canada, with success. “On behalf of FSD, I would like to thank Mr. Cugliari for his contributions to the board. We wish him all the best in his future endeavours,” said Anthony Durkacz, founder, interim CEO and executive co-chairman of the company. “We also welcome Dr. Kotra and Mr. Romano to the board of directors. Their combined wealth of knowledge and experience we believe will be valuable.”
About FSD Pharma Inc
FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.